GSK is set to acquire the exclusive rights for Syndivia’s preclinical antibody-drug conjugate (ADC), which is currently in ...

NICE recommends Bayer’s Nubeqa® (darolutamide) plus androgen deprivation therapy as a treatment option for patients with hormone-sensitive metastatic prostate cancer Nubeqa® (darolutamide) plus ...

The global oncology market is rapidly shifting toward smarter drug-delivery systems that enhance efficacy, reduce toxicity and improve patient outcomes. Traditional oral or IV drugs often face poor ...

Orphan Drug Designation The purpose of the Orphan Product program is to support the development and evaluation of new treatments for rare diseases. FDA grants Orphan Drug designation to ...

For patients with metastatic primary pNETs, resection is associated with improved survival outcomes but also linked to perioperative complications.

A new study underway at St. David’s Surgical Hospital could help men recover faster and live a better quality of life after ...